These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30863034)

  • 1. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
    Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S; Lee YB; Choe SJ; Lee WS
    Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
    Shanshanwal SJ; Dhurat RS
    Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
    Gupta AK; Charrette A
    J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dutasteride in Androgenetic Alopecia: An Update.
    Arif T; Dorjay K; Adil M; Sami M
    Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis.
    Gupta AK; Venkataraman M; Talukder M; Bamimore MA
    JAMA Dermatol; 2022 Mar; 158(3):266-274. PubMed ID: 35107565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
    Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
    J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
    Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
    J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
    Fertig RM; Gamret AC; Darwin E; Gaudi S
    Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy.
    Choi S; Kwon SH; Sim WY; Lew BL
    J Dermatol; 2024 May; 51(5):684-690. PubMed ID: 38321615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.
    Boyapati A; Sinclair R
    Australas J Dermatol; 2013 Feb; 54(1):49-51. PubMed ID: 22686691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
    Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
    Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
    Gupta AK; Talukder M; Williams G
    J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
    Gupta AK; Mays RR; Dotzert MS; Versteeg SG; Shear NH; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2112-2125. PubMed ID: 29797431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
    Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
    BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
    Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M;
    J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
    Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
    Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.